[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tendinopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tendinopathy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,74,100,129,163,190,218,240,271,297,329,351,386,411],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100568425","effectiveness-and-safety-of-ostenil-tendon-in-the-treatment-of-pain-and-restricted-mobility-in-tendon-disorders-100568425",false,"NCT06681051","Effectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders","Inclusion Criteria:\n\n* Patient aged between 18 and 99 years\n* Diagnosis of symptomatic tendinopathy (patella tendon, peroneal tendon, medial epicondylus humeri or iliotibial band)\n* Physician's recommendation to use OSTENIL® TENDON prior to recruitment\n* Signed informed consent\n\nExclusion Criteria:\n\n* Presence of any contra-indication or precautionary condition listed in the instructions for use, i.e.,\n\n  * Ascertained hypersensitivity to any of the OSTENIL® TENDON constituents\n  * Known pregnancy or breast feeding\n  * Acute trauma\n* Use of the following treatments (the given time intervals refer to the date of inclusion):\n\n  * Local\\* OSTENIL® TENDON or other hyaluronic acid (HA) treatment within the last 6 months\n  * Local\\* platelet-rich plasma (PRP) treatment within the last 3 months\n  * Local\\* corticosteroid treatment (without time restriction)\n  * Local\\* extracorporeal shock wave therapy (ESWT) within the last 4 weeks\n  * Local\\* phytotherapy (e.g., Traumeel®) within the last 4 weeks\n  * Local\\* surgical intervention (without time restriction)\n  * Systemic corticosteroid treatment within the last 4 weeks\n  * Repeated use of non-steroidal anti-inflammatory drugs (NSAID) and\u002For other analgesics within the last week\n  * Physiotherapy (therapeutic exercises and physical therapy), ortheses, transcutaneous electrical nerve stimulation (TENS) or acupuncture within the last week\n* Diagnosis of chronic inflammatory disease (e.g. rheumatoid arthritis, Bechterew disease, Crohn's disease, etc.) prior to inclusion\n* Participation in a clinical investigation within the last 6 months\n* Vulnerable patient (individual who is unable to fully understand all aspects of the study that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response \\[including persons needing legally designated representatives, illiterate persons or persons with insufficient knowledge of local language\\])\n\n(\\* local refers to the treatment of the study-relevant tendon)","ALL","18 Years","99 Years",{"count":19,"type":20},84,"ESTIMATED","OBSERVATIONAL","PMCF study to further substantiate the effectiveness and safety of OSTENIL® TENDON in the overall as well as indication-specific treatment of pain and restricted mobility in four different tendon disorders (patella tendon, peroneal tendon, medial epicondylus humeri and iliotibial band) in a real-life clinical setting when used according to the instructions for use.",[24],"Tendinopathy",[26,27,28,29],"tendinopathy","hyaluronan","tendon","hyaluronic acid","RECRUITING","2026-07-01",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2024-11-25",{"date":38,"type":20},"2026-10",{"name":40,"class":41},"TRB Chemedica AG","INDUSTRY",5,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100523831","phase-1-managing-chronic-tendon-pain-by-metformin-100523831","NCT06100822","Managing Chronic Tendon Pain by Metformin","Managing Chronic Tendon Pain by Repurposing Metformin","Inclusion Criteria:\n\n* Willing and able to provide informed consent for participation\n* Clinical diagnosis of Achilles tendinopathy\n* Pain disability index score of between 20 - 70 points (0-100 scale VISA-A)\n* Sonopalpation tenderness with tendon thickening and\u002For loss of fibrillary architecture.\n* Ability to read, speak, and understand English\n\nExclusion Criteria:\n\n* Any intervention (corticosteroids or other orthobiologic intervention as injection) to targeted tissue within the last 6 months.\n* Previous Achilles tendon surgery.\n* Known platelet abnormality or hematological disorder.\n* Presence of other conditions that might affect the functional scale of the indexed limb.\n* Unwillingness to be randomized.\n* Body Mass Index (BMI) greater than 30.\n* Occult tear in the indexed tendon.\n* Systemic inflammatory disease.\n* Use of fluoroquinolone in the past 6 months.\n* Subjects must not be pregnant or breastfeeding, or planning to become pregnant or breastfeed during the course of the trial\n* Chronic kidney disease (eGFR \\\u003C60)\n* Diagnosis of diabetes mellitus or elevated HbA1c at screening (\\> 6.5)\n* Unable to take an oral medication in a non crushable pill form\n* Taking metformin presently or within the last 6 months\n* History of allergy to metformin\n* History of lactic acidosis or elevated lactate at screening (\\> 2.2)\n* Severe Hepatic dysfunction\n* Currently taking a diabetic medication such as sitagliptin, saxagliptin, linagliptin, alogliptin, sitagliptin with metformin\n* Currently taking a Carbonic anhydrase inhibitor such as topiramate, zonisamide, acetazolamide, dichlorphenamide, methazolamide\n* Currently taking cimetidine","50 Years",{"count":52,"type":20},40,"INTERVENTIONAL",[55],"PHASE1","The purpose of the current exploratory clinical trial is to determine the effect of oral ingestion of metformin (OIM) in non-diabetic patients with chronic Achilles tendon pain. The trial has two aims; 1) to assess the effects of OIM treatment on tendon pain, and 2) to determine the effects of OIM capsules on tendon healing and repair. Twenty participants will be treated with metformin capsules for 16 weeks combined with a home exercise program. A comparison group of 20 participants will be treated with placebo tablets along with home exercise program.",[24,58,59],"Chronic Pain","Achilles Tendinopathy",[61,62,59,58],"Achilles Tendon","Metformin","2026-06-02",{"date":65,"type":34},"2026-06-04",{"date":67,"type":34},"2024-05-24",{"date":69,"type":20},"2026-09-30",{"name":71,"class":72},"James Wang","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100640618","human-tendon-tissue-collection-100640618","NCT07606092","Human Tendon Tissue Collection","Human Tendon Tissue Collection for In Vitro Models and Tissue Analysis","Inclusion Criteria:\n\n* 18 years or older\n* Scheduled to undergo orthopaedic lower limb surgery that involve tendon tissue waste\n* Have provided informed consent to take part in the study\n\nExclusion Criteria:\n\n* Under the age of 18\n* Unable or unwilling to give informed consent (including those with limited English proficiency)\n* Cases where tendon tissue is required for clinical care and therefore not surplus.",{"count":82,"type":20},400,"The goal of this study is to improve understanding of tendon health and disease by using surplus tendon tissue that is routinely removed during planned orthopaedic surgeries in adults. The main questions it aims to answer are:\n\n\\- What can tendon tissue and tendon cells tell us about how healthy and diseased tendons function?\n\nParticipants will not undergo any extra procedures. Instead, researchers will use only tissue that is already being removed as part of normal surgical care and would otherwise be discarded.\n\nParticipants will:\n\n* Be asked for permission (consent) before their surgery to donate any surplus tendon tissue.\n* Have a small piece of tendon tissue (normally waste material) collected during their planned operation.\n* Allow the research team to access some non-identifiable medical information (such as age, reason for surgery, and relevant medical history) to help interpret research findings.\n\nWhat the researchers will do with the donated tissue:\n\n* Isolate different types of human tendon cells.\n* Build advanced laboratory cellular models to study how tendon diseases develop.\n* Analyse whole tendon tissue sections to understand cell types, tissue organisation, and disease-related changes.\n\nThis study does not involve testing treatments, and it does not change any aspect of a participant's clinical care. Although there is no direct benefit to participants, the donated tissue may help researchers develop better ways to study tendon injuries and improve future treatment options for tendon disease.",[24,85,86,87],"Musculoskeletal Diseases or Conditions","ACL Surgery","Achilles Tendon Surgery",[89],"Tendon tissue collection","NOT_YET_RECRUITING","2026-05-18",{"date":93,"type":34},"2026-05-26",{"date":95,"type":20},"2026-06",{"date":97,"type":20},"2031-06",{"name":99,"class":72},"Queen Mary University of London",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":53,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":73},"100634524","ultrasound-guided-percutaneous-needle-tenotomy-pnt-vs-percutaneous-ultrasonic-needle-tenotomy-put-for-gluteal-tendinosis-100634524","NCT07540806","Ultrasound-Guided Percutaneous Needle Tenotomy (PNT) vs Percutaneous Ultrasonic Needle Tenotomy (PUT) for Gluteal Tendinosis","Inclusion Criteria:\n\n* Diagnosis of gluteal (medius and\u002For minimus) tendinosis confirmed clinically and with ultrasonography or MRI\n* Failure to improve after 3 months of nonoperative treatment\n* Symptoms present for longer than 3 months\n\nExclusion Criteria:\n\n* Patients with concomitant injuries or pain\n* Full thickness tears of the affected tendon\n* Prior corticosteroid injection of the affected tendon within the last 3 months\n* Prior PNT of the affected tendon\n* Significant abnormalities of bony or tendon morphology","75 Years",{"count":108,"type":20},110,[110],"NA","The goal of this study is to determine if a newer tenotomy technique utilizing an ultrasound needle is more effective than the traditional tenotomy technique utilizing a simple hypodermic needle for gluteal tendinosis. The main questions it aims to answer are:\n\n1. Is pain from the gluteal tendinosis improved with either technique, and, if so, is there a difference in the improvement between techniques?\n2. Is there an improvement in function for gluteal tendinosis, and, if so, is there a difference between techniques?",[24,113,114],"Tendinosis","Gluteal Tendinitis",[24,113,116,117,118,119],"Gluteal tendinosis","Tenotomy","Percutaneous needle tenotomy","Percutaneous ultrasonic tenotomy","2026-05-13",{"date":122,"type":34},"2026-05-15",{"date":124,"type":20},"2026-06-01",{"date":126,"type":20},"2028-04-01",{"name":128,"class":72},"University of Colorado, Denver",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":53,"phases":139,"briefSummary":140,"conditions":141,"keywords":150,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":73},"100610737","platelet-rich-plasma-for-musculoskeletal-conditions-100610737","NCT07231471","Platelet Rich Plasma for Musculoskeletal Conditions","PRP for MSK","Inclusion Criteria:\n\n* 18+ years old\n* Musculoskeletal pathology that may benefit from a PRP injection\n* Failed other conservative treatments\n\nExclusion Criteria:\n\n* No active malignancy\n* No active infection in the area of injection\n* No platelet disorder\n* No active systemic infections\n* No patients currently undergoing dialysis",true,{"count":138,"type":20},10000,[110],"The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction.\n\nThis will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.",[142,143,144,145,146,147,148,149,24],"Osteoarthritis (OA)","Osteoarthritis (OA) of the Knee","Osteoarthritis (OA) of the Hip","Osteoarthritis (OA) of the Shoulder","Osteoarthritis Ankle","Elbow Osteoarthritis","Epicondylitis of the Elbow","Plantar Fasciitis of Both Feet",[151,152,153,24],"PRP","Platelet Rich Plasma","Osteoarthritis","2026-05-05",{"date":156,"type":34},"2026-05-06",{"date":158,"type":34},"2025-12-29",{"date":160,"type":20},"2035-01-01",{"name":162,"class":72},"University of Utah",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":53,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":73},"100611995","efficacy-of-therapeutic-percutaneous-electrolysis-vs-laser-therapy-in-supraspinatus-tendinopathy-100611995","NCT07247825","Efficacy of Therapeutic Percutaneous Electrolysis vs Laser Therapy in Supraspinatus Tendinopathy.","Efficacy of Therapeutic Percutaneous Electrolysis vs Laser Therapy in Supraspinatus Tendinopathy. Randomized Clinical Trial.","Inclusion Criteria:\n\n* Signing of informed consent both to participate in the study and to undergo invasive physiotherapy techniques.\n* Presence of symptoms (inflammation or pain) ≥ 4 weeks.\n* Positive palpation test of the supraspinatus tendon.\n* Men and women over 18 years of age.\n* Score of 3 or higher on the shoulder pain analogue scale.\n* Adequate cognitive ability for understanding.\n* Limited range of motion.\n* Rotator cuff tendinopathy confirmed by ultrasound at the study centre, either due to tendon inflammation, presence of hypoechoic areas, calcification, fibrillar disorganisation and\u002For neovascularisation in the supraspinatus muscle.\n* Pain in the proximal lateral part of the arm that worsens with abduction.\n\nExclusion Criteria:\n\n* Any related acute or chronic musculoskeletal disease that may affect the results of the study.\n* Presence of neuropathic pain such as lumbar radiculopathy, which may affect the results of the study.\n* Not receiving the treatment sessions and assessments of the study.\n* History of glenohumeral fracture and rheumatoid arthritis.\n* Rheumatic, neurological or structural polymyalgia affecting the joint.\n* Pregnancy.\n* Patients with cardiovascular disease.\n* Patients with neurological disease.\n* Local infection.\n* Tumours.\n* Belonephobia.\n* Taking anticoagulants or antiplatelet agents.\n* Infiltrative and\u002For rehabilitative treatment in the two months prior to recruitment.\n* Treatment with another intervention during the study.","65 Years",{"count":52,"type":20},[110],"Supraspinatus tendinopathy (SE) is one of the main pathologies that cause functional alterations in the glenohumeral joint. It reduces the quality of life of the population suffering from this injury. This pathology is the most frequent cause of pain in this joint. Symptoms are aggravated by repetitive work performed at or above shoulder height and sports that involve movements above the head.\n\nSingle-blind randomised clinical trial. The participants in this study will be patients selected from the ValleSur physiotherapy clinic in Ávila from January to May 2026. These patients will be diagnosed beforehand by an orthopaedic surgeon through a complete series of orthopaedic and complementary diagnostic tests. Following the clinical examination conducted by the principal investigator to verify the presence of tendinopathy in the supraspinatus and identify the selection criteria in the selected participants. Ultrasound imaging will be used to select the area to be treated. A single-blind clinical trial with a randomised design will be conducted, in which the evaluator will be blinded to assess the short- and medium-term efficacy of treatment with ultrasound-guided electrolysis. The results will then be compared with another intervention already performed with laser therapy for the same pathology and at the same centre. - Common part of the treatment: Participants included in the study receive one intervention, with four evaluations: pre-intervention, post-intervention, 24 hours and one week after the intervention.\n\n\\- Invasive procedure: The patient is placed in a prone position with their feet outside the treatment table. Before beginning the intervention, the physiotherapist uses sterile gloves and examines the area to be treated using a linear probe ultrasound scanner, 2D study, in B mode and Doppler, to identify the target tissue safely and guaranteein B-mode and Doppler mode, to identify the target tissue safely and ensure the effectiveness of the technique. (10) Once the target area has been located, an ultrasound palpation is performed to correlate the ultrasound image with the patient's clinical condition. This image is frozen in order to measure the distance from the skin to the target tissue and select the needle, in this case 0.30 x 25 mm in length (Agupunt, Madrid, Spain) CE. (16,17) The physiotherapist then thoroughly cleans the area using sterile gauze and 2% aqueous chlorhexidine. The ultrasound probe is placed back on the target tissue, the needle inserted into the handpiece is introduced, and the contact electrode is placed in the upper area close to the needle to close the circuit. Once positioned in the area to be treated, the CE-certified electrolysis device for the percutaneous application of EPTE® galvanic current (IONCLINICS \\& DEIONIC SL, Av.\n\nAntonio Almela 29, 46250 Alcudia, Valencia, Spain), the intensity is programmed, which in this case is 360 µA, and the treatment time, 1 minute and 20 seconds, and the 'ON' button to start the technique, and the current begins to rise progressively until it reaches 360 µA. Once the intensity is reached, the time countdown begins (1 minute and 20 seconds).",[24],[176,177,178,179,180],"electrolysis","Quality of life","pain","laser","range of motion","2026-04-28",{"date":183,"type":34},"2026-05-04",{"date":185,"type":34},"2026-01-10",{"date":187,"type":20},"2026-08-31",{"name":189,"class":72},"Universidad Pontificia de Salamanca",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":53,"phases":199,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":73},"100635483","vibratory-anesthesia-on-pain-following-corticosteroid-injections-100635483","NCT07553273","Vibratory Anesthesia on Pain Following Corticosteroid Injections","The Effect of Vibratory Anesthesia on Patient Pain Perception in Corticosteroid Injections of the Upper Extremity","Inclusion Criteria:\n\n* Any patient of the Principal Investigator who has clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow where treatment with corticosteroid injection is indicated.\n* Participants who voluntarily consent to participate in the study and sign consent forms.\n* Participants who complete all numeric pain rating scales\n* Patients aged ≥ 18 years old\n\nExclusion Criteria:\n\n* Participants who opt out of the study or withdraw consent\n* Participants who are determined to be without capacity to consent to study participation or injection procedure by principal investigator\n* Participants with inability to complete numeric pain rating scales\n* Participants with known allergies to triamcinolone acetonide, lidocaine, or bupivicaine\n* Participants without clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow.\n* Participants where treatment with corticosteroid injection is not indicated bilaterally.\n* Patients ≤ 18 years old",{"count":198,"type":20},165,[110],"This research study aims to evaluate injectional pain at the site of needle insertion for corticosteroid injections (CSI) of the upper extremity depending on different modes of anesthetics. Each individual's perception of pain upon receiving a CSI with two out of three modes of anesthesia (control\u002Fno anesthesia, vibrational anesthesia, vapo-coolant anesthesia) will be utilized to compare these variables and determine the method that is associated with the least pain.",[202,24,203,204,205],"Bilateral Arthritis of Wrist","Arthropathy","Compression Neuropathy","Bilateral Arthritis of Hands",[207,208,209],"Pain in Hand","Pain in Elbow","Pain in Wrist","2026-04-27",{"date":183,"type":34},{"date":213,"type":20},"2026-04",{"date":215,"type":20},"2027-04",{"name":217,"class":72},"The University of Texas Medical Branch, Galveston",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":53,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":73},"100512251","clinical-improvement-obtained-by-endoscopic-ilio-psoas-tenotomy-lesser-trochanter-versus-acetabular-notch-100512251","NCT05950022","Clinical Improvement Obtained by Endoscopic Ilio-Psoas Tenotomy (Lesser Trochanter Versus Acetabular Notch)","Study Evaluating the Clinical Improvement Obtained by Endoscopic Tenotomy of the Ilio-Psoas, at the Level of the Lesser Trochanter Versus at the Level of the Acetabular Notch, on Psoas Cup Impingements After Total Hip Prosthesis","ETIPIC","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Definite diagnosis of iliopsoas tendinopathy due to conflict between the tendon and the prosthetic cup;\n* Failure of first-line conservative treatment;\n* Planned endoscopic tenotomy;\n* Affiliation to the social security scheme;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Revision total hip prosthesis, multiple operations prior to tenotomy;\n* Other surgical or medical interventions planned during the study;\n* Participation in another clinical trial, or during a period of exclusion from another clinical trial;\n* Pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding;\n* Patient deprived of liberty or under guardianship or curatorship or unable to give consent.",{"count":227,"type":20},108,[110],"The purpose of the study is to assess Oxford Hip Score at baseline, at 2 months and at over 12 months.",[24],"2026-03-27",{"date":233,"type":34},"2026-04-01",{"date":235,"type":34},"2023-12-19",{"date":237,"type":20},"2028-12",{"name":239,"class":72},"GCS Ramsay Santé pour l'Enseignement et la Recherche",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":15,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":53,"phases":252,"briefSummary":253,"conditions":254,"keywords":260,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":73},"100523389","embolization-treatment-of-chronic-refractory-shoulder-tendinopathy-100523389","NCT06095050","Embolization Treatment of Chronic Refractory Shoulder Tendinopathy","Efficacy of Lipiodol Embolization for Chronic Tendinopathy of the Rotator Cuff","ELECTRC","Inclusion Criteria:\n\n1. Male, female, transgender female, transgender male, non-binary\n2. Moderate to severe shoulder pain (VAS \\> 40)\n3. Pain refractory to at least 6 months of physician-directed conservative therapy (analgesics or injections or PT), including a minimum of 6 weeks of PT\n4. Willing, able, and mentally competent to provide informed consent and to tolerate angiography and physical therapy\n\nExclusion Criteria:\n\n1. History of peripheral arterial disease or peripheral artery disease symptoms including claudication, diminished or absent upper\u002Flower extremity pulses, or known upper extremity arterial atherosclerosis or occlusion that would limit selective angiography\n2. Known history of anaphylaxis to iodinated contrast agents or gadolinium based contrast\n3. Acute kidney injury\n4. Allergy to poppy seeds or lipiodol\n5. Renal dysfunction as defined by serum creatinine \\>1.6 dl\u002Fmg or eGFR \\\u003C60 obtained within 30 days of procedure.\n6. Uncorrectable coagulopathy (platelet count \\\u003C 50,000, international normalized ratio \\>1.8 within 30 days of procedure\n7. Active systemic or local upper extremity infection\n8. Patient pregnant, intending to become pregnant during the study.\n9. Prior shoulder replacement surgery\n10. Prior rotator cuff repair surgery\n11. Previous history of complete full-thickness tear of the rotator cuff\n12. Presence of non-MRI compatible devices (e.g., non-compatible cardiac pacemaker).","21 Years","80 Years",{"count":251,"type":20},41,[110],"This is a randomized controlled trial in which patients with moderate to severe shoulder pain (Visual Analog Scale (VAS) \\> 40), in the setting of rotator cuff tendinopathy refractory to conservative treatment, will be enrolled.\n\nThe primary aim of the study is to estimate the effect of transcatheter arterial embolization (TAE) with physical therapy (PT) vs PT alone on the change in shoulder pain at 12-month follow up. Scientific objectives also include an assessment of safety of the intervention, assessment of changes in Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity score, Shoulder Pain and Disability Index (SPADI) scores, MRI Tendinopathy Score between the TAE + PT and PT groups.",[255,24,256,257,258,259],"Shoulder Pain","Rotator Cuff Tendinitis","Rotator Cuff Tendinosis","Embolization","Arterial Occlusion",[178,261,26],"shoulder pain","2026-02-04",{"date":264,"type":34},"2026-02-06",{"date":266,"type":34},"2025-01-16",{"date":268,"type":20},"2028-04-21",{"name":270,"class":72},"Brigham and Women's Hospital",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":136,"sex":15,"minAge":16,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":73},"100527052","tracking-of-red-blood-cells-using-super-resolution-ultrasound-in-persons-with-healthy-or-overuse-injured-tendons-100527052","NCT06142747","Tracking of Red Blood Cells Using Super Resolution Ultrasound in Persons With Healthy or Overuse Injured Tendons","SUper-Resolution Ultrasound Imaging of Erythrocytes (SURE) in Normal and Tendinopathic Tendons","SURE-TEND","Inclusion Criteria:\n\n* 18 to 70 years of age.\n* BMI below 30.\n* Able to lie still for 1 minute.\n* Capable of providing signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Dementia.\n* Smoking.\n* Diabetes.\n* Arthritis.\n* Current or historical injuries to the tendon or surrounding tissue aside from tendinopathy.\n* Medical or surgical treatments for their tendinopathy that may influence blood flow.","70 Years",{"count":281,"type":20},135,"The goal of this observational study is to test whether a new ultrasound method, called SUper Resolution ultrasound imaging of Erythrocytes (SURE), can image the small blood vessels found in tendons of persons with a tendon overuse injury (tendinopathy). The main questions it aims to answer are:\n\n* Is the method sensitive enough to detect the smallest blood vessels\n* What information about the blood flow can be obtained (flow velocity, pressure, shape of the vessels)\n* Can the flow in an injured tendon be distinguished from that of a healthy one\n\nParticipants will receive a non-invasive ultrasound examination of their Achilles (heel) or patellar (knee) tendon, using an advanced high frequency research ultrasound system.\n\nResearchers will compare participants with either an Achilles or patellar tendon overuse injury to participants with healthy tendons, to see if there are distinct differences in the blood vessels that could help diagnose and treat the injuries.",[24],[285,61,286,287],"Tendon Overuse Injury","Patellar Tendon","Ultrasonography","2026-01-20",{"date":290,"type":34},"2026-01-22",{"date":292,"type":34},"2024-02-08",{"date":294,"type":20},"2028-01",{"name":296,"class":72},"University Hospital Bispebjerg and Frederiksberg",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":53,"phases":306,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":328},"100461721","phase-4-ketorolac-in-upper-extremity-tendinopathy-and-arthropathy-100461721","NCT05292339","Ketorolac in Upper Extremity Tendinopathy and Arthropathy","Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy","Inclusion Criteria:\n\n* Age 18 or older,\n* symptomatic tendinopathy or arthropathy of the shoulder, elbow, hand, or wrist who have not undergone prior surgical treatment for their condition.\n* Diagnoses may include trigger finger, De Quervain's tenosynovitis, radiocarpal osteoarthritis, first carpometacarpal (CMC) joint osteoarthritis, metacarpophalangeal joint osteoarthritis, or proximal interphalangeal joint osteoarthritis.\n\nExclusion Criteria:\n\n* Patients under the age of 18,\n* Patients who have undergone prior triamcinolone or ketorolac injections within the past 6 months,\n* Patients who have undergone prior surgical treatment for their hand condition,\n* Patients with allergy or contraindication to triamcinolone or ketorolac injection,\n* Patients with an active infection at the treatment site \\[active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. white blood cells (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)\\].",{"count":305,"type":20},160,[307],"PHASE4","Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the duration of symptomatic relief exist for arthropathy and tendinopathy of these joints.\n\nThe goal of this study is to evaluate the efficacy of ketorolac and triamcinolone injections for common shoulder, elbow, wrist, and hand tendinopathy or arthropathy.\n\nParticipants will be blinded to the treatment received. The duration of an individual participant's participation in this study is 24 weeks. During this time period, patients will be asked to return to the clinic for an in-person follow-up 6 weeks after the injection with either ketorolac or triamcinolone) in order to assess participants' outcomes. All work related to this project will take place at the Emory Sports Medicine Complex, Emory Executive Park, Emory Musculoskeletal Institute, the Emory University Orthopaedic and Spine Hospital, and the Emory Saint Joseph's Hospital. This study will add to existing knowledge by providing further insight into how wrist arthropathy should be most optimally and conservatively managed.",[153,24,203],[311,312,313,314,315,316,317,318],"First Carpometacarpal Joint","Ketoralac","metacarpophalangeal joint osteoarthritis","trigger finger","De Quervain's tenosynovitis","radiocarpal osteoarthritis","Triamcinolone","Upper extremity","2025-08-19",{"date":321,"type":34},"2025-08-24",{"date":323,"type":34},"2023-01-31",{"date":325,"type":20},"2027-07",{"name":327,"class":72},"Emory University",4,{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":170,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":73},"100320818","assessing-the-tendons-with-shear-wave-elastography-100320818","NCT03456778","Assessing the Tendons With Shear Wave Elastography","Assessing the Efficacy of the Treatment of Tendinopathy With Shear Wave Elastography","Inclusion Criteria for Asymptomatic Volunteers:\n\n* Patients presenting at the study location with lower extremity pain without tendon involvement\n\nInclusion Criteria for Symptomatic Volunteers:\n\n* Patients presenting at the study location with a clinical diagnosis of tenalgia\n* Diagnosis of tendinopathy confirmed by ultrasound\n\nExclusion Criteria:\n\n* Pregnancy\n* History of tendinopathy or surgery and morphologic abnormalities\n* History of systemic, metabolic, endocrine diseases, or psoriasis\n* History of treatment with corticosteroids, estrogens, long term quinolone antibiotics, and cholesterol drugs",{"count":337,"type":20},150,"The purpose of this study is to utilize Shear Wave Elastography (SWE) to study the viscoelastic properties of tendons to understand the functional differences between normal\u002Fasymptomatic and symptomatic tendon states. The study will also assess the degree of tendon healing following standard of care treatment.",[24],[341,342],"Sonographic imaging","Shear Wave Elastography","2025-08-11",{"date":345,"type":34},"2025-08-14",{"date":347,"type":34},"2018-02-27",{"date":349,"type":20},"2026-07",{"name":327,"class":72},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":279,"enrollmentInfo":359,"targetDuration":4,"studyType":53,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":73},"100474945","evaluation-of-collagen-based-medical-device-treatment-combined-with-physiotherapy-in-subjects-with-achilles-tendinopathy-100474945","NCT05464498","Evaluation of Collagen-based Medical Device Treatment Combined With Physiotherapy in Subjects With Achilles Tendinopathy.","Evaluation of Collagen-based Medical Device Treatment Combined With Physiotherapy in Subjects With Achilles Tendinopathy. Multicenter Randomized Clinical Investigation; AKITENMED STUDY.","AKITENMED","Inclusion Criteria:\n\n* Male and female subjects aged 18 to 70 years;\n* Subjects with tendon pain for not more than 24 weeks;\n* Subjects with clinically diagnosed and ultrasonographically confirmed insertional\u002Fnoninsertional\u002Fmystic tendinopathy;\n* Subjects with a VISA A score between 50 and 75;\n* VAS ≥ 5;\n* Subjects able to understand and answer the SF12 questionnaire;\n* Subjects able to understand and sign the informed consent.\n\nExclusion Criteria:\n\n* subjects who have had surgery in the investigated area or lower extremity;\n* subjects who have previously undergone physiotherapy.\n* subjects with autoimmune diseases;\n* subjects with peripheral neuropathy;\n* subjects with calcific tendinopathy\n* subjects with pain of direct traumatic origin;\n* subjects with local\u002Fsystemic infections;\n* subjects with neoplastic diseases;\n* subjects with gout;\n* subjects on corticosteroid treatment at the time of enrollment;\n* subjects who have used corticosteroids or fluoroquinolones in the three months prior to enrollment;\n* subjects who have used NSAIDs in the week prior to enrollment;\n* subjects who are pregnant and lactating;\n* subjects with contraindications to acetaminophen use;\n* allergy to porcine collagen.",{"count":360,"type":20},72,[110],"Achilles tendinopathy is a condition characterized by inflammation of the Achilles tendon. Achilles tendinopathies are classified into insertional tendinitis and noninsertional tendinitis. Insertional tendinitis involves the lower part of the tendon, where the tendon inserts at the level of the calcaneus, and can affect even patients who are not particularly athletically active. Noninsertional tendinitis occurs when the fibers in the middle portion of the tendon are affected, affects young and athletic people the most, and has a high incidence (30-50%) in middle-aged individuals.\n\nConsidering that there are no strong evidence-based guidelines in the area of treatment of achilles tendinopathy, the aim of this research project is to understand through a multicenter, randomized clinical investigation the impact of treatment with a porcine collagen-based medical device administered in the peri-tendon area in combination with physiotherapy on pain reduction and functional improvement of the investigated tendon.",[24,364,59,365],"Insertional Achilles Tendinopathy","Peritendinitis",[367,368,369,370,371,372,373,374,375,376],"Eccentric strengthening","Collagene Medical Device","Physiotherapy","Peritendinous area","Infiltration","Type I collagen","Eccentric strengthening protocol","Pain Visual Analog Scale","12-Item Short Form Survey","Victorian Institute of Sport Assessment- Achilles questionnaire","2025-08-01",{"date":379,"type":34},"2025-08-03",{"date":381,"type":34},"2022-06-13",{"date":383,"type":20},"2026-01-13",{"name":385,"class":41},"Guna S.p.a",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":393,"targetDuration":4,"studyType":53,"phases":395,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":73},"100594916","the-effectiveness-of-different-exercise-approaches-in-biceps-brachii-long-head-tendinopathy-100594916","NCT07025668","The Effectiveness of Different Exercise Approaches in Biceps Brachii Long Head Tendinopathy","Effects of Different Exercise Approaches on Tendon Cross-sectional Area and Pain in Biceps Brachii Long Head Tendinopathy","Inclusion Criteria:\n\n* Having shoulder pain lasting 3 months or more\n* Without a history of surgery, having a diagnosis of shoulder rotator cuff tendinopathy, rotator cuff stage 1-2 tear or subacromial impingement, and having been diagnosed with secondary biceps long head tendinopathy by a physician\n* Pain level during activity \\> 3 according to the visual analog scale\n* Patients who have been informed about the study and have given written consent to participate in the study will be included in the study.\n\nExclusion Criteria:\n\n* Acute shoulder injury\n* History of shoulder and cervical surgery\n* Limitation of passive range of motion\n* History of local corticosteroid injection within the last 12 months\n* Patients who cannot comply with the exercise program will be excluded from the study.",{"count":394,"type":20},36,[110],"This study was planned to analyze the changes in tendon cross-sectional area and shoulder pain with different exercise approaches applied in biceps brachii long head tendinopathy.",[398,24],"Sports Physical Therapy",[400,26,401,261],"biceps brachii","tendon cross-sectional area","2025-06-15",{"date":404,"type":34},"2025-06-17",{"date":406,"type":34},"2025-05-09",{"date":408,"type":20},"2025-11-30",{"name":410,"class":72},"Hacettepe University",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":53,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":73},"100560942","real-dry-needling-and-placebo-dry-needling-applied-with-and-without-ultrasound-guidance-on-the-infraspinatus-muscle-100560942","NCT06583707","Real Dry Needling and Placebo Dry Needling Applied With and Without Ultrasound Guidance on the Infraspinatus Muscle","Effect of the Application of Real Dry Needling and Placebo Dry Needling Applied With and Without Ultrasound Guidance on the Infraspinatus Muscle in Shoulder Pain and Functionality in Patients Diagnosed With Rotator Cuff Tendinopathy","DN-INFR-RCT","Inclusion Criteria:\n\nPatients aged between 18 and 60 years. Patients diagnosed with rotator cuff tendinopathy by a physician. The physician must have determined this diagnosis based on an imaging test: ultrasound or MRI. Presence of a taut band in the infraspinatus muscle with active trigger points that reproduce the patient\\'s symptoms upon pressure.\n\n\\-\n\nExclusion Criteria:\n\nHigh-level athletes, patients diagnosed with capsulitis, patients with a history of humeral or scapular fracture, patients with a complete or partial rotator cuff tear, patients diagnosed with cancer, and patients with any contraindications related to dry needling, patients who have previously undergone shoulder surgery, patients with a history of shoulder dislocation, patients diagnosed with fibromyalgia, patients taking medication for shoulder pain, and pregnant patients\n\n\\-","60 Years",{"count":421,"type":20},76,[110],"The infraspinatus muscle is one of the four muscles that form the rotator cuff. The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. This study includes a self-directed exercise plan for rotator cuff tendinopathy. Variables such as strength, shoulder functionality level, grip strength, and active range of motion will be measured. As part of the intervention, two dry needling sessions will be performed, 14 days apart, along with two different exercise programs. Three measurements will be taken, and the intervention will last for 6 weeks. The sample will be divided into four equal groups: Group 1: ultrasound-guided real dry needling; Group 2: ultrasound-guided placebo dry needling; Group 3: non-ultrasound-guided real dry needling; and Group 4: non-ultrasound-guided placebo dry needling",[24,425],"Rotator Cuff",[427,428,429,24,430,431],"Dry needling","Rotator cuff","Pain","ultrasound-guided","exercise","2024-09-03",{"date":434,"type":34},"2024-09-04",{"date":436,"type":20},"2024-09-23",{"date":438,"type":20},"2025-03",{"name":440,"class":72},"University of Alcala"]